260 related articles for article (PubMed ID: 38571944)
21. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Garcia JS; Kim HT; Murdock HM; Ansuinelli M; Brock J; Cutler CS; Gooptu M; Ho VT; Koreth J; Nikiforow S; Romee R; Shapiro R; DeAngelo DJ; Stone RM; Bat-Erdene D; Ryan J; Contreras ME; Fell G; Letai A; Ritz J; Lindsley RC; Soiffer RJ; Antin JH
Blood Adv; 2024 Feb; 8(4):978-990. PubMed ID: 38197938
[TBL] [Abstract][Full Text] [Related]
23. Perspective on measurable residual disease testing in acute myeloid leukemia.
Walter RB
Leukemia; 2024 Jan; 38(1):10-13. PubMed ID: 37973819
[No Abstract] [Full Text] [Related]
24. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E; Lehander M; Virding Culleton S; Yang W; Li Y; Karpanen T; Yoshizato T; Rustad EH; Nielsen MM; Bollineni RC; Tran TT; Delic-Sarac M; Gjerdingen TJ; Douvlataniotis K; Laos M; Ali M; Hillen A; Mazzi S; Chin DWL; Mehta A; Holm JS; Bentzen AK; Bill M; Griffioen M; Gedde-Dahl T; Lehmann S; Jacobsen SEW; Woll PS; Olweus J
Nat Cancer; 2023 Oct; 4(10):1474-1490. PubMed ID: 37783807
[TBL] [Abstract][Full Text] [Related]
25. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
Heitmann JS; Schlenk RF; Dörfel D; Kayser S; Döhner K; Heuser M; Thol F; Kapp-Schwoerer S; Labrenz J; Edelmann D; Märklin M; Vogel W; Bethge W; Walz JS; Große-Hovest L; Steiner M; Jung G; Salih HR
J Hematol Oncol; 2023 Aug; 16(1):96. PubMed ID: 37587502
[TBL] [Abstract][Full Text] [Related]
26. Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells.
Palau A; Segerberg F; Lidschreiber M; Lidschreiber K; Naughton AJ; Needhamsen M; Jung LA; Jagodic M; Cramer P; Lehmann S; Carlsten M; Lennartsson A
Leukemia; 2023 Sep; 37(9):1830-1841. PubMed ID: 37495775
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cells for acute myeloid leukemia.
Fetsch V; Zeiser R
Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J; Urrutia S; Loghavi S; Short NJ; Issa GC; Maiti A; Abbas HA; Daver NG; Pemmaraju N; Pierce S; Chien KS; Sasaki K; Kadia TM; Hammond DE; Borthakur G; Patel K; Ravandi F; Kantarjian HM; Garcia-Manero G; DiNardo CD
Blood; 2023 Nov; 142(19):1647-1657. PubMed ID: 37441846
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Wang Y; Yang K; Shao R; Huang F; Fan Z; Chi P; Xu Y; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Lin R; Chen Y; Tu S; Zhang Y; Sun J; Huang X; Liu Q
Lancet Haematol; 2023 Aug; 10(8):e600-e611. PubMed ID: 37414062
[TBL] [Abstract][Full Text] [Related]
30. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J; Hamadani M; Wu J; Al Malki MM; Martens MJ; Runaas L; Elmariah H; Rezvani AR; Gooptu M; Larkin KT; Shaffer BC; El Jurdi N; Loren AW; Solh M; Hall AC; Alousi AM; Jamy OH; Perales MA; Yao JM; Applegate K; Bhatt AS; Kean LS; Efebera YA; Reshef R; Clark W; DiFronzo NL; Leifer E; Horowitz MM; Jones RJ; Holtan SG;
N Engl J Med; 2023 Jun; 388(25):2338-2348. PubMed ID: 37342922
[TBL] [Abstract][Full Text] [Related]
31. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years.
Shimony S; Fell G; Chen EC; Tsai HK; Wadleigh M; Winer ES; Garcia JS; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Lindsley RC; Stone RM
Blood Adv; 2023 Sep; 7(18):5354-5358. PubMed ID: 37163357
[TBL] [Abstract][Full Text] [Related]
32. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
Maurer K; Ho VT; Inyang E; Cutler C; Koreth J; Shapiro RM; Gooptu M; Romee R; Nikiforow S; Antin JH; Wu CJ; Ritz J; Soiffer RJ; Kim HT
Blood Adv; 2023 Aug; 7(15):3903-3915. PubMed ID: 37156098
[TBL] [Abstract][Full Text] [Related]
33. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
34. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Fathi AT; Kim HT; Soiffer RJ; Levis MJ; Li S; Kim AS; DeFilipp Z; El-Jawahri A; McAfee SL; Brunner AM; Amrein PC; Mims AS; Knight LW; Kelley D; Bottoms AS; Perry LH; Wahl JL; Brock J; Breton E; Marchione DM; Ho VT; Chen YB
Clin Cancer Res; 2023 Jun; 29(11):2034-2042. PubMed ID: 37014667
[TBL] [Abstract][Full Text] [Related]
35. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Garcia-Manero G; Goldberg AD; Winer ES; Altman JK; Fathi AT; Odenike O; Roboz GJ; Sweet K; Miller C; Wennborg A; Hickman DK; Kanagal-Shamanna R; Kantarjian H; Lancet J; Komrokji R; Attar EC; Sallman DA
Lancet Haematol; 2023 Apr; 10(4):e272-e283. PubMed ID: 36990622
[TBL] [Abstract][Full Text] [Related]
36. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC; Aldoss I; DiPersio J; Cuglievan B; Stone R; Arellano M; Thirman MJ; Patel MR; Dickens DS; Shenoy S; Shukla N; Kantarjian H; Armstrong SA; Perner F; Perry JA; Rosen G; Bagley RG; Meyers ML; Ordentlich P; Gu Y; Kumar V; Smith S; McGeehan GM; Stein EM
Nature; 2023 Mar; 615(7954):920-924. PubMed ID: 36922593
[TBL] [Abstract][Full Text] [Related]
37. MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F; Stein EM; Wenge DV; Singh S; Kim J; Apazidis A; Rahnamoun H; Anand D; Marinaccio C; Hatton C; Wen Y; Stone RM; Schaller D; Mowla S; Xiao W; Gamlen HA; Stonestrom AJ; Persaud S; Ener E; Cutler JA; Doench JG; McGeehan GM; Volkamer A; Chodera JD; Nowak RP; Fischer ES; Levine RL; Armstrong SA; Cai SF
Nature; 2023 Mar; 615(7954):913-919. PubMed ID: 36922589
[TBL] [Abstract][Full Text] [Related]
38. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A; Thomas M; Grünmeier R; Lesch S; Rohrbacher L; Igl V; Briukhovetska D; Benmebarek MR; Vick B; Dede S; Müller K; Xu T; Dhoqina D; Märkl F; Robinson S; Sendelhofert A; Schulz H; Umut Ö; Kavaka V; Tsiverioti CA; Carlini E; Nandi S; Strzalkowski T; Lorenzini T; Stock S; Müller PJ; Dörr J; Seifert M; Cadilha BL; Brabenec R; Röder N; Rataj F; Nüesch M; Modemann F; Wellbrock J; Fiedler W; Kellner C; Beltrán E; Herold T; Paquet D; Jeremias I; von Baumgarten L; Endres S; Subklewe M; Marr C; Kobold S
Nat Biotechnol; 2023 Nov; 41(11):1618-1632. PubMed ID: 36914885
[TBL] [Abstract][Full Text] [Related]
39. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Penter L; Liu Y; Wolff JO; Yang L; Taing L; Jhaveri A; Southard J; Patel M; Cullen NM; Pfaff KL; Cieri N; Oliveira G; Kim-Schulze S; Ranasinghe S; Leonard R; Robertson T; Morgan EA; Chen HX; Song MH; Thurin M; Li S; Rodig SJ; Cibulskis C; Gabriel S; Bachireddy P; Ritz J; Streicher H; Neuberg DS; Hodi FS; Davids MS; Gnjatic S; Livak KJ; Altreuter J; Michor F; Soiffer RJ; Garcia JS; Wu CJ
Blood; 2023 Apr; 141(15):1817-1830. PubMed ID: 36706355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
